Cleary Gottlieb Reps Alkermes In $960M Elan Unit Buy
Alkermes Inc. said Monday it would pay $960 million to buy the drug technology unit of fellow pharmaceutical company Elan Corp. PLC in a deal that will broaden Alkermes' drug portfolio...To view the full article, register now.
Already a subscriber? Click here to view full article